Welcome to Paid Research Studies


Browse Locations ... United States» ... Pennsylvania» ... Bethlehem






  • Condition:   Hypertrophic Cardiomyopathy
    Interventions:   Drug: GS-6615;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting - verified January 2015

  • Condition:   Lupus
    Interventions:   Drug: BMS-931699;   Drug: Placebo matching BMS-931699
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2014

  • Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Drug: Erlotinib Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adult Alveolar Soft Part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Synovial Sarcoma;   Non-Metastatic Childhood Soft Tissue Sarcoma;   Stage IB Adult Soft Tissue Sarcoma;   Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: Pazopanib Hydrochloride;   Drug: Ifosfamide;   Drug: Doxorubicin Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Chronic Kidney Disease;   Autosomal Dominant Polycystic Kidney Disease
    Interventions:   Drug: Tolvaptan (OPC-41061);   Drug: Placebo
    Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting - verified January 2015

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Daunorubicin Hydrochloride;   Drug: Pegaspargase;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin Hydrochloride;   Drug: Thioguanine;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Etoposide;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Anemia
    Interventions:   Drug: GSK1278863;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified January 2015

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: alectinib;   Drug: crizotinib
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified January 2015

  • Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
    Interventions:   Drug: Canagliflozin;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
    Recruiting - verified January 2015

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: sarilumab SAR153191 (REGN88);   Device: Auto-injector (AID);   Device: Pre-filled Syringe (PFS)
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified January 2015

  • Conditions:   Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Biological: Rituximab;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Dexamethasone;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Melanoma
    Intervention:  
    Sponsors:   Sanjiv Agarwala, MD;   Merck Sharp & Dohme Corp.
    Recruiting - verified January 2015

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified January 2015

  • Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting - verified January 2015

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: RO5424802;   Drug: RO5424802
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified January 2015

  • Conditions:   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Diabetic Nephropathy
    Interventions:   Drug: Atrasentan;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting - verified January 2015

  • Condition:   Diabetic Foot Ulcers
    Interventions:   Drug: DSC127;   Drug: placebo vehicle gel;   Drug: Standard of Care gel, Aquasite
    Sponsors:   Derma Sciences, Inc.;   Integrium
    Recruiting - verified January 2015

  • Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
    Intervention:   Drug: Olaparib 300mg tablets
    Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified January 2015

  • Conditions:   Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Metastatic or Unresectable Cutaneous Melanoma
    Interventions:   Drug: MEK162;   Drug: Dacarbazine
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified January 2015

  • Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
    Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
    Recruiting - verified January 2015

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified January 2015

  • Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: RE-021 (Sparsentan);   Drug: Irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting - verified January 2015

  • Conditions:   Childhood B Acute Lymphoblastic Leukemia;   Childhood Burkitt Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma
    Interventions:   Biological: Rituximab;   Drug: Prednisone;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Leucovorin Calcium;   Drug: Therapeutic Hydrocortisone;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Malignant Neoplasm of Breast;   Breast Diseases;   Ductal Breast Carcinoma
    Intervention:   Radiation: Intraoperative radiation therapy (IORT)
    Sponsors:   University of California, San Francisco;   H. Lee Moffitt Cancer Center and Research Institute;   Northwestern University;   Los Angeles Center for Women's Health
    Recruiting - verified January 2015

  • Condition:   Asthma
    Interventions:   Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg;   Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg;   Drug: Mometasone Furoate MDI 100 mcg;   Drug: Mometasone Furoate MDI 200 mcg;   Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI;   Drug: Prednisone/prednisolone
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified January 2015

  • Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
    Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
    Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
    Recruiting - verified January 2015

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Proteinuria;   Idiopathic Membranous Nephropathy
    Interventions:   Drug: Repository Corticotropin Injection;   Drug: Placebo
    Sponsor:   Questcor Pharmaceuticals, Inc.
    Recruiting - verified January 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Daunorubicin Hydrochloride;   Drug: Mitoxantrone Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Bortezomib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Fungal Infection;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Influenza, Human
    Interventions:   Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified January 2015

  • Condition:   Intracerebral Hemorrhage
    Intervention:   Drug: Nicardipine hydrochloride
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Medical University of South Carolina;   National Institute of Neurological Disorders and Stroke (NINDS);   Johns Hopkins University;   University of Michigan
    Recruiting - verified January 2015

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Rheumatoid Arthritis
    Intervention:   Drug: SAR153191 (REGN88)
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified January 2015

  • Condition:   Brain Injuries
    Intervention:   Drug: NNZ-2566
    Sponsor:   Neuren Pharmaceuticals Limited
    Recruiting - verified January 2015

  • Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
    Interventions:   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Cisplatin;   Radiation: Internal Radiation Therapy
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified January 2015

  • Conditions:   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: Isotretinoin;   Biological: Sargramostim;   Biological: Monoclonal Antibody Ch14.18;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014